Defining Treatment Outcomes and Genetic Architecture in Idiopathic Toe Walking* (ITW)

January 12, 2026 updated by: Jeremy Bauer, Shriners Hospitals for Children
To compare and contrast the clinical, gait and parent-reported outcomes following either non-operative (casting) or operative treatment for children with idiopathic toe walking (ITW) and determine whether there are specific genes associated with ITW.

Study Overview

Status

Completed

Detailed Description

Toe walking is a very common diagnosis in children with a prevalence of 5% -24%. Persistent toe walking in children over 3 years of age often results in parental concern, provoking multiple medical visits, and a range of interventions. Additionally, toe walking has both social implications and concerns for increased foot and ankle pain in those with contracture. Idiopathic toe walking (ITW) is a diagnosis of exclusion and affirming the diagnosis, ascertaining if intervention is indicated, and determining the optimal timing and intervention strategy are not well defined in the literature. As a family history of toe walking is reported in many children with ITW, there is a strong possibility that a subset of children may have a genetic cause for the condition which may impact the clinical course and outcome of treatment. Several approaches to intervention have been suggested to address toe-walking including: observation, therapy, casting, botulinum toxin A as well as surgery to lengthen the gastroc-soleus complex at the level of the calf or Achilles tendon. The purpose of this multi-center study is to examine a well-defined cohort of children with ITW utilizing a combination of quantitative measurement tools, parent reported outcomes, and whole genome sequencing to promote an evidence-based approach to orthopaedic management of this population. One hundred and eighty children who meet the inclusion/exclusion criteria for this study will be recruited from 8 participating SHC sites (POR, NCA, SLC, CHI, PHL, SPO, GRN, LEX) and treated with either serial casting or surgery. Children will be assessed 3 times over 1 year (Baseline, 6-months and 1-year post intervention). A series of screening as well as delineated inclusion/exclusion criteria will be used to ensure the diagnosis of ITW. Clinical assessments, radiographs and 3-D gait analysis utilizing electromyography and a multi-segment foot model will be used to determine if there are differences in the range of motion, gait kinematics and kinetics, motor synergies and foot contact patterns following casting or surgery. Whole genome sequencing will be used to determine if there is a genetic basis for ITW can be identified. Analysis will focus on 1) comparing and contrasting the short and long-term outcomes following non-operative (casting) and surgical intervention to determine if one approach is more efficacious, 2) identify potential genetic determinants for ITWp and 3) identify the factors that mediate and moderate intervention efficacy. The knowledge gained from this study will promote development of an evidence-based and personalized approach to the management of ITW.

Study Type

Interventional

Enrollment (Actual)

65

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • California
      • Sacramento, California, United States, 95817
        • Shriners Hospitals for Children
    • Illinois
      • Chicago, Illinois, United States, 60707
        • Shriners Hospitals for Children
    • Kentucky
      • Lexington, Kentucky, United States, 40508
        • Shriners Hospitals for Children
    • Oregon
      • Portland, Oregon, United States, 97239
        • Shriners Hospitals for Children
    • Pennsylvania
      • Philadelphia, Pennsylvania, United States, 19140
        • Shriners Hospitals for Children
    • South Carolina
      • Greenville, South Carolina, United States, 29605
        • Shriners Hospitals for Children
    • Utah
      • Salt Lake City, Utah, United States, 84103
        • Shriners Hospitals for Children
    • Washington
      • Spokane, Washington, United States, 99204
        • Shriners Children's Spokane

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  1. Diagnosis of Idiopathic Toe Walking Persistent (ITWp)
  2. Between the ages of 6-18 years
  3. Passive dorsiflexion dorsiflexion with knee extension between -10 plantar flexion - + 5 degrees of dorsiflexion, DiGiovanni defined an isolated gastrocnemius contracture as maximum passive ankle dorsiflexion as < 5 degrees with the knee in full extension

Exclusion Criteria:

  1. Diagnosis of Autism or autism spectrum disorder
  2. Presence of any indicators of trauma, neuromuscular influence or neurogenic influence as identified by using the Toe Walking Tool

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Serial Casting
Repeated casts weekly until desired dorsiflexion range achieved
Repeated casts weekly until desired dorsiflexion range achieved
Active Comparator: Surgery
Surgical procedure to the gastrocnemius and/or plantar fascia
Surgical procedure to the gastrocnemius and/or plantar fascia

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Gait parameters: Velocity
Time Frame: Baseline, 6 months post intervention, 1 year post intervention
Velocity (m/s) will be assessed during walking in the gait lab.
Baseline, 6 months post intervention, 1 year post intervention
Three dimensional Gait Analysis:Kinematics (degrees)
Time Frame: Baseline, 6 months post intervention, 1 year post intervention

Kinematics as calculated from the reflective markers placed on the skin during the computerized gait analysis will allow for the computation of knee, ankle and foot kinematics during walking.

Knee Kinematics (measured in degrees): Knee angle at IC, knee extension at midstance, peak knee flexion in swing.

Ankle kinematics (measured in degrees): Ankle angle at IC, ankle angle at midstance, angle range of 3rd rocker, average ankle angle in stance, average ankle angle in swing.

Multisegment Foot Motion (measured in degrees): ankle complex flexion, rotation, 2)midfoot flexion, rotation and 3) hallux varus and flexion rotation.

Baseline, 6 months post intervention, 1 year post intervention
Dynamic Motor Control Index during Walking (Walk-DMC)
Time Frame: Baseline, 6 months post intervention, 1 year post intervention
Walk-DMC is a measure of motor control which is calculated from the dynamic muscle activity from five muscles (rectus femoris, medial and lateral hamstrings, tibialis anterior and gastrocnemius, bilaterally)
Baseline, 6 months post intervention, 1 year post intervention
Three dimensional Gait Analysis:Kinetics (nm/kg)
Time Frame: Baseline, 6 months post intervention, 1 year post intervention
Ankle kinetics: peak plantarflexion moment and power absorption at loading response, power generation at terminal stance will be calculated from the force plates and gait kinematics during the walking gait analysis.
Baseline, 6 months post intervention, 1 year post intervention
Quantitative Assessment of Toe Walking
Time Frame: Baseline, 6 months post intervention, 1 year post intervention
Quantitative assessment of toe walking will be obtained with the in-shoe system the NURVV/RUN. The NURVV/RUN calculates the percentage of foot contact time spent on the rearfoot, midfoot and forefoot.
Baseline, 6 months post intervention, 1 year post intervention
Pediatric Outcomes Data Collection Instrument
Time Frame: Baseline, 6 months post intervention, 1 year post intervention
Daily functional musculoskeletal health will be assessed with the Pediatric Outcomes Data Collection Instrument, a questionnaire that contains 108 questions in seven domains including four functional assessment areas: upper extremity functioning, transfers and basic mobility, sports and physical function, and comfort/pain. Items have different weights, with possible scores range from three (often, sometimes, rarely or never) to five (none, very mild, moderate, severe, very severe). For most items a lower score indicates higher functioning or a more positive quality of life.
Baseline, 6 months post intervention, 1 year post intervention
Gait Parameters:Stride Length (m)
Time Frame: Baseline, 6 months post intervention, 1 year post intervention
Stride Length (m) will be assessed during walking in the gait lab.
Baseline, 6 months post intervention, 1 year post intervention

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Passive Range of Motion
Time Frame: Baseline, 6 months post intervention, 1 year post intervention
Dorsiflexion with and without knee flexion, popliteal angle are measured with a goniometer and measured in degrees
Baseline, 6 months post intervention, 1 year post intervention
Muscle Strength
Time Frame: Baseline, 6 months post intervention, 1 year post intervention
A hand-held dynamometer (HHD) will be used to assess quantitative muscle strength, via a "make test" for ankle dorsiflexors/plantarflexors, and foot inverters/everters, bilaterally.
Baseline, 6 months post intervention, 1 year post intervention

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Coactivation Tool
Time Frame: Baseline
The coactivation tool utilizes electromyographic activity during two lower extremity activities to determine whether there is coactivation between the gastrocnemius and the quadriceps during resistive knee extension bilaterally. Abnormalities in the muscle activation pattern may be an indication of a diagnosis other than idiopathic toe walking.
Baseline
Bruininks-Oseretsky Test of Motor Proficiency (BOT-2)
Time Frame: Baseline
The subtests of Bilateral Coordination and Balance which form the Body Coordination composite score will be used ascertain coordination of children with ITW relative to age-matched norms to help characterize the population and determine if coordination influences outcome. Higher scores indicate better balance and bilateral coordination.
Baseline
Genomics
Time Frame: Baseline
Whole Genome Sequencing will be done on the participant and both biological parents (if possible) to determine if the patient and their parents have any genetic abnormalities in genes that may be associated with toe walking and to determine if the cohort as a whole have potential new genes that may be indicative of toe walking.
Baseline
Selective Motor Control
Time Frame: Baseline
Selective Voluntary Motor Control Scale is a simple clinical measure of the ability to selectively control the muscles. Selective motor control of the hip, knee, ankle, subtalar, and toe joints will be assessed using the Selective Voluntary Motor Control tool. A total of 10 points is possible for each side with higher numbers indicating more selective control.
Baseline
The Toe Walking Tool
Time Frame: Baseline
This novel tool designed for screening out children who toe walk for other reasons such as neurogenic, neuromuscular, or traumatic. If any questions are answered as yes, the principal investigator will review to determine whether a diagnosis of idiopathic toe walking is appropriate.
Baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Jeremy Bauer, MD, Shriners Hospitals for Children-Portland

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2022

Primary Completion (Actual)

December 31, 2025

Study Completion (Actual)

December 31, 2025

Study Registration Dates

First Submitted

November 20, 2023

First Submitted That Met QC Criteria

March 4, 2024

First Posted (Actual)

March 12, 2024

Study Record Updates

Last Update Posted (Estimated)

January 14, 2026

Last Update Submitted That Met QC Criteria

January 12, 2026

Last Verified

July 1, 2024

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Idiopathic Toe Walking

Clinical Trials on Serial Casting

Subscribe